Latest news

• CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

  look at two other recent rejections – Novartis’ Revolade (eltrombopag) for severe aplastic anaemia and PTC Therapeutics’ Duchenne muscular dystrophy drug Translarna (ataluren).

• FDA clears Dova drug for liver-related low blood platelets

  Drug is in the same class as Novartis’ Promacta/Revolade. Dova Pharmaceuticals has won its first product approval, getting a green light from the FDA for Doptelet as a treatment for ... Doptelet is in the same class as Novartis’ Promacta/Revolade

• Novartis’ Promacta receives US breakthrough therapy designation

  Known as Revolade in most countries outside the US, Promacta gained its breakthrough therapy designation following positive data, which 52% of treatment-naïve severe aplastic anaemia (SAA) patients achieved complete response ... Regulatory filings for a

• CHMP backs orphan drugs Uptravi and Coagadex

  new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or

• Novartis bags EU approvals for three ex-GSK drugs

  Revolade, Tafinlar and Mekinist all receive regulatory approval. Novartis has been granted EU approvals to three drugs acquired as part of its asset swap deal with GlaxoSmithKline, which closed earlier this ... year. The Swiss company announced this